Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Concurrent loss of the Y chromosome in cancer and T cells impacts outcome
Concurrent loss of the Y chromosome in cancer and T cells impacts outcome
Basu M, Xiao J-F, Kailasam Mani SK, Qu F, Lin Y, Duex J, Ye H, Neang V, Theodorescu D . 2025. Genes driving three-dimensional growth of immortalized cells and cancer . Cell Death & Disease. Article number: 442(16).
— 2025cited by 0position: selected
The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients.
Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy.
Feldman LER, Mohapatra S, Jones RT, Scholtes M, Tilton CB, Orman MV, Joshi M, Deiter CS, Broneske TP, Qu F, et al. 2024. Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy . Science Advances. 10(50).
— 2024cited by 0position: selected
Osipov A, Nikolic O, Gertych A, Parker S, Hendifar A, Singh P, Filippova D, Dagliyan G, Ferrone CR, Zheng L, et al. 2024. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients . Nature Cancer. 5(2):299–314.
— 2024cited by 0position: selected
Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin.
<scp>CD24</scp> targeting with <scp>NK‐CAR</scp> immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct <scp>CD24</scp> interaction partners
Abdel-Hafiz HA, Schafer JM, Chen X, Xiao T, Gauntner TD, Li Z, Theodorescu D . 2023. Y chromosome loss in cancer drives growth by evasion of adaptive immunity . Nature. 619(7970):624–631.
— 2023cited by 0position: selected
de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made AC, Boevé ER, van der Schoot DK, Nieuwkamer B, Janssen EA, Mahmoudi T, et al. 2023. Non–muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin . Science Translational Med
— 2023cited by 0position: selected
FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti–PD-L1 Immune Checkpoint Therapy
Assessment of Luminal and Basal Phenotypes in Bladder Cancer
Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression
<i>TERT</i> promoter mutations and telomerase reactivation in urothelial cancer
Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
Frequent truncating mutations of STAG2 in bladder cancer
Translation Initiation Factor eIF3b Expression in Human Cancer and Its Role in Tumor Growth and Lung Colonization
Discovery and validation of urinary biomarkers for detection of renal cell carcinoma
Telomerase in Bladder Cancer: Back to a Better Future?
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings